Short course chemotherapy in children suffering from drug resistant tuberculosis

Klevno, N. I.; Aksenova, Valentina; Kazakov, Alexey; Kovalevskaya, E. B.

doi:10.21292/2075-1230-2021-99-2-34-39

Cited by 4 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the Russian Federation, bedaquiline is successfully used in the treatment of patients with MDR and XDR TB, which made it possible to carry out the presented data analysis. In recent years, studies have been conducted with the inclusion of bedaquiline in children of various ages who had a severe and progressive course of MDR TB [ 51 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Старшинова

Dovgalyk

Belyaeva³

et al. 2022

Antibiotics

View full text Add to dashboard Cite

In the conditions of the continued growth of multiple- and extensive drug-resistant tuberculosis, use of the new highly effective anti-tuberculosis drugs in this patient category is of great relevance. The aim of the study was determination the efficacy of treatment in patients with multidrug- and extensive drug-resistant tuberculosis using bedaquiline based on studies published in the Russian Federation. Materials and methods: The authors analyzed data published in studies from 2014 to 2022; 41 publications were included in total and 17 articles corresponded to the study design. The results of treatment of 1404 tuberculosis patients with MDR/XDR TB were described. Bedaquiline was used according to the standard scheme with a description of the treatment results after 24–26 weeks. Treatment efficacy was estimated according to accepted criteria. Results of the study: The analysis showed that the treatment efficacy on conversion was achieved in 79.5% of cases (95% Cl 76.5–82.3), and recovery was observed in 82.0% of cases (95% Cl 78.6–85.1). Departure from the therapy was observed in rare cases (9.8%; 95% Cl 7.9–12.2). Deaths were recorded in 6.5% of cases (95% Cl 4.9–8.3), which were associated with the severe disease and concomitant pathology in 74.3%. The development of adverse events was noted in half of the patients (55.7%); however, bedaquiline cancellation occurred in a few cases (7.0%; 95% Cl 3.0–13.0). From analyzing data in patients with MDR and XDR TB, the efficacy of treatment was 89.9% (95% Cl 85.9–93.2) and 71.9% (95% Cl 66.2–77.1), respectively. Conclusion: Use of bedaquiline in treatment makes it possible to achieve recovery of patients with MDR/XDR TB in 82.0% of cases with patients dropping out of treatment in 9.8%. At the same time, in patients with MDR TB, recovery was achieved in 89.9% of cases, while in patients with XDR TB, 71.9% of cases recovered.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Старшинова

Dovgalyk

Belyaeva³

et al. 2022

Antibiotics

View full text Add to dashboard Cite

show abstract

Systematic review of efficacy and safety of shorter regimens for drug-resistant tuberculosis (DR-TB) in children

Jain,

Malik,

Kaur

et al. 2024

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

Justification of Chemotherapy Duration in Patients with Multiple and Pre-Extensive Drug Resistant Tuberculosis in the Russian Federation

Gayda¹,

Abramchenko

Romanova³

et al. 2023

Tuberk. bolezni lëgk.

View full text Add to dashboard Cite

The objective: to justify the optimal duration of chemotherapy with Lzd and Bdq by evaluating the long-term treatment outcomes in patients with multiple/pre-extensive drug resistant (MDR/preXDR) tuberculosis who interrupted treatment at different time points.Subjects and Methods. 800 patients with MDR/preXDR tuberculosis were enrolled in the study, they were from all regions of the Russian Federation and they started a course of chemotherapy with regimens containing Lzd and Bdq in 2017-2018. All patients who interrupted their chemotherapy (124) were divided at 4 groups. Group 1-43 patients who received less than 90 doses, Group 2-37 patients who received from 91 to 180 doses, Group 3-39 patients who received from 181 to 270 doses, and Group 4-5 patients who received from 271 to 360 doses of anti-tuberculosis drugs.Results. In Group 3, the effectiveness of reaching a favorable outcome during observation for 3-4 years made 53.8% in 21/39, which was comparable to the effectiveness of treatment with a 24-month course of chemotherapy (2017 – 58.0 and 2018 – 52.1%). The treatment duration of patients from Group 3 was additionally analyzed, the arithmetic mean of the number of administered doses makes 262 ± 15, which allowed recommending 9-month courses of chemotherapy.

show abstract

Short course chemotherapy in children suffering from drug resistant tuberculosis

Cited by 4 publications

References 5 publications

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Efficacy of Tuberculosis Treatment in Patients with Drug-Resistant Tuberculosis with the Use of Bedaquiline: The Experience of the Russian Federation

Systematic review of efficacy and safety of shorter regimens for drug-resistant tuberculosis (DR-TB) in children

Justification of Chemotherapy Duration in Patients with Multiple and Pre-Extensive Drug Resistant Tuberculosis in the Russian Federation

Contact Info

Product

Resources

About